NCT05275465

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH-006 in Healthy Volunteers

Name: Clinical Trial NCT05275465
Creator: Huahui Health
Keywords: Hepatitis B, HH-006, Phase 1, drug, clinical trial, Australia

A Randomized, Placebo-controlled, Single-Ascending Dose Phase Ia Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH-006 in Healthy Volunteers

Huahui Health·Phase 1·ClinicalTrials.gov·drugRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Hepatitis B
Drug/Device/Intervention: HH-006
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Huahui Health
Location: Brisbane, Australia

Timeline & enrollment

Phase: Phase 1
Start date: Apr 11, 2022
End date: Jan 30, 2023
Enrollment: 33 participants

Primary outcome

Number of participants with treatment emergent adverse events (TEAEs),Severity of treatment emergent adverse events as measured by CTCAE v 5.0,Duration of treatment emergent adverse events

Summary

Huahui Health is developing a treatment for Hepatitis B virus. This study is designed to evaluate the safety and tolerability of HH-006, a hepatitis virus neutralizing monoclonal antibody in healthy volunteers, and to determine its pharmacokinetic profile and immunogenicity.

ICD-10 classifications

Acute hepatitis BAcute hepatitis B without delta-agent and without hepatic comaAcute delta-(super)infection in chronic hepatitis BChronic viral hepatitis B without delta-agentChronic viral hepatitis B without delta-agent : other and unspecified phase

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT05275465
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT05275465 through Pure Global AI's free database. This Phase 1 trial is sponsored by Huahui Health and is currently Recruiting. The study focuses on Hepatitis B. Target enrollment is 33 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.